Skip to main content Skip to main navigation menu Skip to site footer

Identification of tumor infiltrating lymphocyte CD8 in Indonesian colorectal cancer population: a cross-sectional study

  • Elit Irawan ,
  • Kiki Lukman ,
  • Nurhayat Usman ,
  • Bambang Am Am Setya Sulthana ,
  • Reno Rudiman ,
  • Deny Budiman ,
  • Prapanca Nugraha ,
  • Etis Primastari ,


Link of Video Abstract:


Background: Colorectal cancer is now the third most common cancer both globally and in Indonesia. An important component of the adaptive immune system, tumor-infiltrating lymphocytes (TILs) cluster of differentiation 8 (CD8+) are key in the immune response to malignancies, which were previously believed to be the primary initiators of anti-tumor immunity. A higher TIL CD8+ levels in the tumor microenvironment and a better prognosis have been associated with anticancer benefits in a number of cancers. This study aimed to describe the characteristics of colorectal cancer patients with increased tumor-infiltrating lymphocyte CD8+ expression and their relationship with clinicopathological features.

Methods: A cross-sectional investigation was conducted. Patients in the digestive surgery division with colorectal cancer served as the study's research subjects. There were 36 study subjects that were randomly selected from the available specimens. Examination of tumor-infiltrating lymphocytes CD8+ expression was carried out by the immunohistochemistry method.

Result: Expression of tumor-infiltrating lymphocytes CD8+, was positive in nine (25%) patients, and normal expression was shown in 27 (75%) patients. Most of the patients had adenocarcinomas histologically (91.7%), and 66.7% of patients were older than 50, with 77.8% of the tumors located at the rectum. Univariate analysis of the clinicopathological characteristics related to the tumor-infiltrating lymphocytes CD8+, showed a non-significant relationship statistically (p > 0.05).

Conclusion: There was no relationship between clinicopathological characteristics and tumor-infiltrating lymphocyte CD8+ expression in colorectal cancers.


  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
  2. Kimman M, Norman R, Jan S, Kingston D, Woodward M. The burden of cancer in member countries of the Association of Southeast Asian Nations (ASEAN). Asian Pacific journal of cancer prevention. 2012;13(2):411-420.
  3. Kokki I, Papana A, Campbell H, Theodoratou E. Estimating the incidence of colorectal cancer in South East Asia. Croatian Medical Journal. 2013;54(6):532-540.
  4. Schatoff EM, Leach BI, Dow LE. Wnt signaling and colorectal cancer. Current colorectal cancer reports. 2017;13(2):101-110.
  5. Kaminski MF, Robertson DJ, Senore C, Rex DK. Optimizing the quality of colorectal cancer screening worldwide. Gastroenterology. 2020;158(2):404-417.
  6. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. The Journal of Immunology. 2014;192(12):5451-5458.
  7. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, et al. Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology. 2012;1(8):1323-1343.
  8. Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Experimental biology and medicine. 2011;236(5):567-579.
  9. Zhang N, Bevan MJ. CD8+ T cells: foot soldiers of the immune system. Immunity. 2011;35(2):161-168.
  10. Liu Y, Zhou N, Zhou L, Wang J, Zhou Y, Zhang T, et al. IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor. Nature immunology. 2021;22(3):358-369.
  11. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumors: impact on clinical outcome. Nature Reviews Cancer. 2012;12(4):298-306.
  12. Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nature Reviews Cancer. 2020;20(11):662-680.
  13. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-1964.
  14. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. New England journal of medicine. 2005;353(25):2654-2666.
  15. Camus M, Tosolini M, Mlecnik B, Pages F, Kirilovsky A, Berger A, et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer research. 2009;69(6):2685-2693.
  16. Cuschieri S. The STROBE guidelines. Saudi journal of anaesthesia. 2019;13(Suppl 1):S31.
  17. Lotfollahzadeh S, Recio-Boiles A, Cagir B. Colon Cancer. [Updated 2022 Dec 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from:
  18. Lotfollahzadeh S, Kashyap S, Tsoris A, Recio-Boiles A, Babiker HM. Rectal Cancer. [Updated 2022 Dec 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from:
  19. Rudiman R, Wijaya A, Sribudiani Y, Soedjana HS, Wiraswati HL, Primastari, et al. Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study. Annals of Medicine & Surgery. 2023:85(5):1761-1768.
  20. Lukman K, Reza AT, Hasibuan LY, Sribudiani Y, Dewayani BM, Rudiman R, et al. Different clinicopathological characteristics in indonesian colorectal patients with NRAS mutations and HER2 over-expression. Asian Pac J Cancer Prev. 2023;24(4):1373–1377.
  21. Purnama A, Lukman K, Ruchimat T, Rudiman R, Wijaya A, Nugraha P. Vitamin D and diagnostic colonoscopy for colorectal cancer in Indonesian population: a cross-sectional study. Open Access Maced J Med Sci. 2023;11(B):439-445.
  22. Sideras K, Galjart B, Vasaturo A, Pedroza‐Gonzalez A, Biermann K, Mancham S, et al. Prognostic value of intra‐tumoral CD8+/FoxP3+ lymphocyte ratio in patients with resected colorectal cancer liver metastasis. Journal of surgical oncology. 2018;118(1):68-76.
  23. Trabelsi M, Farah F, Zouari B, Jaafoura MH, Kharrat M. An immunoscore system based on CD3+ and CD8+ infiltrating lymphocytes densities to predict the outcome of patients with colorectal adenocarcinoma. OncoTargets and therapy. 2019;12:8663.
  24. Muamar M, Budhi IB, Soewoto W, Agustriani N, Ismail D. The role of post-operative glutamine serum level and one-year survival rate of stage III of colorectal cancer patients: a single center study. Bali Med J. 2022;11(3):1223-1229.
  25. Bai Z, Zhou Y, Ye Z, Xiong J, Lan H, Wang F. Tumor-infiltrating lymphocytes in colorectal cancer: the fundamental indication and application on immunotherapy. Frontiers in Immunology. 2022;12:5926.
  26. Xin H, Zhou C, Wang G, Zhang J, Liu Y, Li B, et al. Heterogeneity of PD-L1 expression and CD8 lymphocyte infiltration in metastatic colorectal cancer and their prognostic significance. Heliyon. 2023;9(2):e13048.

How to Cite

Irawan, E., Lukman, K., Usman, N., Sulthana, B. A. A. S., Rudiman, R., Budiman, D., Nugraha, P., & Primastari, E. (2023). Identification of tumor infiltrating lymphocyte CD8 in Indonesian colorectal cancer population: a cross-sectional study. Bali Medical Journal, 12(2), 1781–1785.